Q: hi folks:
can you please have a quick review on this micra cap?
thank you in advance
can you please have a quick review on this micra cap?
thank you in advance
5i Research Answer:
EPRX was listed in 2021; market cap is now $175M, down 8% this year. It has $8M cash, no revenue, losses and negative cash flow ($37M in the last 12 months). It did raise another $44M recently and says it has enough money until the third quarter of 2026. It has several products in the pipeline, including a Phase II esophagitis product which has shown promising results. But its other products are earlier stage. Insiders own 11% and Bob Disbrow, a well-known BC promoter, owns 8%. It is interesting, but the share price will likely be binary based on future clinical results. We think buyers have lots of time here, and would consider it too high risk to endorse right now.